Company intelligence / Profile preview
InvisiShield Technologies Ltd.
Emeryville, California, United Statesinvisishieldtech.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
In preclinical studies, InvisiShield's engineered intranasal antibodies have effectively neutralized respiratory viruses. Their IS101 candidate has shown robust protection against SARS-CoV-2 variants and has demonstrated disruption of viral transmission in Syrian golden hamster models. IS101 provided at least 10 hours of protection against infection in mice.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Engineered intranasal antibodiesantibody fusion proteins
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Gladstone InstitutesEureka Therapeutics
Beyond the preview
Go deeper on InvisiShield Technologies Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InvisiShield Technologies Ltd..